Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring
This study is looking at whether using a continuous glucose monitor (CGM) and having your glucose levels checked remotely (Remote Patient Monitoring or RPM) can help people with uncontrolled type 2 diabetes better manage their condition. The CGM is a small device that tracks your blood sugar throughout the day, and the RPM means healthcare providers will review this information to help you reach your health goals. The study aims to see if this approach improves your A1c (a measure of average blood sugar over 2-3 months), how much time your blood sugar stays in a healthy range, and your overall feelings about managing diabetes. You might be able to join if you are an adult with type 2 diabetes and your A1c is above 8%. The study is looking for 40 participants and its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 40 participants.
- What's involved
- Participants will wear a continuous glucose monitor (CGM) and have their glucose levels remotely monitored. Your A1c will be measured at baseline, 12, 24, 36, and 52 weeks. Time in range will be measured at baseline, 6, 12, 24, 36, and 52 weeks. Your Problem Areas in Diabetes (PAID) score will be measured at baseline, 12, 24, and 52 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your A1c, time in range, and PAID score will be measured up to 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sushma Reddy, MD · PRINCIPAL_INVESTIGATOR · Diabetes Solutions International
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in A1cBaseline, 12, 24, 36 and 52 weeks
A1c is a blood test that measures the average glucose level over the previous 2 to 3 months. A normal A1c is 5.7 to 6.4%. The usual goal for most people with diabetes is \< 7% or as close to normal as possible without low glucose levels
- Change in time in range (TIR)Baseline, 6, 12, 24, 36 and 52 weeks
TIR measures the percentage of glucose values between 70-180 mg/dl ie the percentage of time spent between 70-180 mg/dl . The usual goal for most individuals with diabetes is to have TIR \> 70%
- Change in Problem Areas in Diabetes (PAID) scoreBaseline, 12, 24 and 52 weeks
PAID is a 20 point questionnaire that assesses diabetes related distress. A lower score indicates less diabetes related distress. A score of \> 40 indicates significant diabetes related distress. Typically the PAID score decreases in response to diabetes care management. An extremely low score (0-10) combined with high glucose levels may be indicative of denial. The score can range from 0 to 125.